C3 Glomerulopathy (C3G) & MPGN Clinical Trials | WeC3G.com
App
Study Name
A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Recruiting

Phase 2

A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN

Recruiting

Phase 2

A Proof of Concept Study for 6 Month Treatment in Patients With C3 Glomerulopathy (C3G)

Recruiting

Phase 2

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Recruiting

Phase 2

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy

Recruiting

Phase 2

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

Recruiting

Phase 2

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

Recruiting

Phase 2

Text/HTML

Last updated: 4/19

Search for the most up-to-date and complete C3G clinical trial information on clinicaltrials.gov here.

Text/HTML
Text/HTML